Anti-Bacterial Agents / pharmacology ; Bacteria, Anaerobic / drug effects* ; Bacteria, Anaerobic / isolation & purification ; Bacterial Infections / drug therapy ; Bacterial Infections / epidemiology ; Bacterial Infections / microbiology ; Bacteroides / drug effects ; Bacteroides fragilis / drug effects ; Clindamycin / pharmacology ; Clostridium perfringens / drug effects ; Drug Resistance, Microbial* ; Humans ; Korea / epidemiology ; Lactams ; Peptostreptococcus / drug effects
Abstract
In previous studies, Bacteroides fragilis group organisms isolated from Korean patients were more frequently resistant to various antimicrobial agents, including clindamycin, than were isolates in other countries. A recent report of increased resistance of Peptostreptococcus species prompted us to include such isolates in a study of antimicrobial susceptibility. anaerobes isolated in 1994 at a tertiary care hospital in Seoul were tested by agar dilution method. None of the B. fragilis group organisms were resistant to imipenem, cefoxitin, chloramphenicol, or metronidazole. However, 6.7% were resistant to ampicillin/sulbactam, 20.2% to cefotetan, 30.3% to piperacillin, 48.3% to cefotaxime, and 42.7% to clindamycin. Almost all of the Clostridium perfringens isolates were susceptible to all of the agents tested, except tetracycline. Peptostreptococcus isolates were susceptible to piperacillin, cefotaxime, and imipenem, while 7.4% were resistant to penicillin G, cefotetan, and metronidazole, and 25.9% were resistant to clindamycin. The isolates resistant to penicillin G, cefotetan, and metronidazole were identified as Peptostreptococcus anaerobius. In conclusion, besides the well-known high rate of resistance of B. fragilis group organisms to clindamycin, the emergence of resistance of Peptostreptococcus species isolates to beta-lactam drugs has become obvious in Korea.